Guidelines for heart transplantation

Netherlands Heart Journal

Volumn 16, Issue 3, 2008, Pages 79-87

  De Jonge, N ^a   Kirkels, J H ^a   Klopping C ^a   Lahpor, J R ^a   Caliskan, K ^b   Maat, A P W M ^b   Brugemann J ^c   Erasmus, M E ^c   Klautz, R J M ^d   Verwey, H F ^d   Oomen, A ^e   Peels, C H ^f   Goluke A E J ^g   Nicastia, D ^h   Koole, M A C ⁱ   Balk, A H M M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

^g Zevenaar Hospital   (Netherlands)

^h GELRE HOSPITALS   (Netherlands)

ⁱ RED CROSS HOSPITAL   (Netherlands)

Author keywords

Guidelines; Heart failure; Heart transplantation

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART FAILURE; ALCOHOLISM; CANCER RECURRENCE; CARDIAC RESYNCHRONIZATION THERAPY; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ABUSE; EXERCISE; HEART ASSIST DEVICE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; INFECTION; LUNG VASCULAR RESISTANCE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NEOPLASM; NETHERLANDS; ORGAN DONOR; PATIENT COMPLIANCE; PATIENT REFERRAL; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PROGNOSIS; PULMONARY HYPERTENSION; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UREA NITROGEN BLOOD LEVEL;

EID: 41749083526     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03086123     Document Type: Review

References (43)

1. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult heart transplantation report-2006. JHLTX 2006;25:869-79.
2. Balk AHHM, Maat APWM, Weimar W, de Jonge N, et al. Heart transplantation: guidelines for the referring cardiologist. Cardiologie 1998;5:702-15.
3. Coppen R, Marquet RL, Friele RD. Het donorpotentieel. Een vergelijking van het donorpotentieel in Nederland en 9 andere West Europese landen. Nivel 2003.
4. Kirkels JH, de Jonge N, Klöpping C, Lahpor JR, van Herwerden LA, Balk AHMM, et al. Heart transplantation in the Netherlands: quo vadis? Neth Heart J 2006;14:425-30.
5. Redfield MM. Heart failure-an epidemic of uncertain proportions. N Engl J Med 2002;347:1442-4.
6. Gardner RS, McDanagh TA, MacDonald M, Dargie HJ, Murday AJ, Petrie MC. Who needs a heart transplant? Eur Heart J 2006;27:770-2.
7. Butler J, Khadim G, Paul KM, Davis SF, Kronenberg MW, Chomsky DB, et al. Selection of patients for heart transplantation en the current era of heart failure therapy. J Am Coll Cardiol 2004;43:787-93.
8. Lahpor JR, de Jonge N, van Swieten HA, Wesenhagen H, Klöpping C, Geertman JH, et al. Left ventricular assist device as bridge to transplantation in patients with end-stage heart failure. Eight year experience with the implantable HeartMate LVAS. Neth Heart J 2002;10:267-71.
9. de Jonge N, Kirkels H, Lahpor JR, Klöpping C, Hulzebos EJ, Brutel de la Rivière A, et al. Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting? J Am Coll Cardiol 2001;37:1794-9.
10. th edition. Elsevier Saunders 2005.
11. The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiologie. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40.
12. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. Circulation 2005;112:1825-52.
13. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
14. Lewis EF, Tsang SW, Fang JC, et al. Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure. J Am Coll Cardiol 2004;43:794-802.
15. Hunt SA, Frazier OH. Mechanical circulatory support and cardiac transplantation. Circulation 1998;97:2079-90.
16. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778- 86.
17. Peterson LR, Schechtman KB, Ewald GA, et al. Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. J Heart Lung Transplant 2003;22:1141-8.
18. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1997;29:1585-90.
19. Robbins M, Francis G, Pashkow FJ, et al. Ventilatory and heart rate responses to exercise. Better predictors of heart failure mortality than peak oxygen consumption. Circulation 1999;100:2411-7.
20. Gitt AK, Wasserman K, Kilkowskis C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation 2002;106:3079-84.
21. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
22. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004;23:1414-22.
23. Rothenburger M, Wichter T, Schmid C. Aminoterminal pro type Bnatriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant 2004;23:1189-97.
24. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, Von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
25. de Jonge N, Vantrimpont PJMJ. Treatment of end-stage heart failure. Neth Heart J 2004;12:548-54.
26. Steimle AE, Stevenson LW, Fonarow GC, et al. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994;23:553-9.
27. Fonarow GC, Adam KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acute decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-80.
28. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581-7.
29. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Lung Transplant 1988;7:331-6.
30. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Lung Transplant 1990;9:526-37.
31. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 2006;25:1024-42.
32. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999;18:549-62.
33. Shapiro PA, Williams DL, Foray AT, Gelman IS, Wukich N, Sciacca R. Psychosocial evaluation and prediction of compliance problems and morbidity after heart transplantation. Transplantation 1995;60:1462-6.
34. Radovancevic B, Poindexter S, Birovljev S, et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 1990;4:309-12.
35. Vantrimpont PJ, van Dalen BM, van Riemsdijk-van Overbeeke IC, Maat AP, Balk AH. Abdominal aortic aneurysms after heart transplantation. J Heart Lung Transplant 2004;23:171-7.
36. Wetering van de J, Weimar CH, Balk AH, Roodnat JL, Holweg CT, Baan CC, et al. The impact of transforming growth factor beta-1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 2006;82:1744-8.
37. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
38. Russo MJ, Chen JM, Kimberly NH, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus. An analysis of the united network of organ sharing database. Circulation 2006;114:2280-7.
39. Lietz K, John R, Burke EA, et al. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation 2001;72:277-83.
40. Modelprotocol postmortale orgaan-en weefseldonatie 2006/2007. Onder redactie van J Ringers. Nederlandse Transplantatie Stichting.
41. Lietz K, Ranjit J, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allograft from older donors versus mortality on the transplant waiting list. Implications for donor selection criteria. J Am Coll Cardiol 2004;43:1553-61.
42. Smits JM, Vanhaecke J, Haverich A, de Vries E, et al. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999. Clin Transpl 2003:89-100.
43. Duport N, Pessione F, Chalem Y, Tuppin P. Marginal heart graft: extended donor criteria and their impact on graft survival. Organs Tissue 2005;2:93-100.